Company Profile
Lexicon Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- LXRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.36 USD (-3.67%)
Close
Last updated: August 6, 2026
840M USD
Market cap
Why the stock is moving
Following the latest company update, “Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates”, LXRX closed down 3.67% at $2.36 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Genetically Informed Drug Discovery
Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases.
Sotagliflozin Franchise
Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor. It is marketed as INPEFA for heart-failure-related indications, while the ZYNQUISTA application targets adults with type 1 diabetes.
Hypertrophic Cardiomyopathy
The SONATA-HCM study evaluates sotagliflozin in hypertrophic cardiomyopathy. Lexicon also maintains development programs in neuropathic pain, obesity and metabolic disease.
Neuropathic-Pain and Metabolic Pipeline
Beyond sotagliflozin, Lexicon maintains discovery, preclinical and clinical candidates in neuropathic pain, obesity and other cardiometabolic disorders.
Future catalysts
Completion of enrollment in SONATA-HCM around mid-2026.
NDA resubmission for ZYNQUISTA around mid-2026.
Topline SONATA-HCM results in the first quarter of 2027.
Recent news
- 01
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Source: Lexicon Pharmaceuticals
- 02
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Source: Lexicon Pharmaceuticals
- 03
- 04
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Source: Lexicon Pharmaceuticals
- 05
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Source: Lexicon Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
Lexicon Pharmaceuticals (LXRX) most recently closed at 2.36 USD, a -3.67% move versus the previous session.
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
Lexicon Pharmaceuticals currently has a market capitalization of 840M USD on BioPharmSignal.
What does Lexicon Pharmaceuticals do?
Genetically Informed Drug Discovery Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases. Sotagliflozin Franchise Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor. It is marketed as INPEFA for heart-failure-related indications, while the ZYNQUISTA application targets adults with...
On which exchange is LXRX stock listed?
Lexicon Pharmaceuticals (LXRX) is associated with NASDAQ, United States, Biopharma.
What is SONATA-HCM?
Completion of enrollment in SONATA-HCM around mid-2026.
Which conditions is Lexicon Pharmaceuticals targeting with SONATA-HCM?
Lexicon Pharmaceuticals is associated with metabolic disease, obesity, diabetes based on its company overview and current catalyst commentary.
How does Lexicon Pharmaceuticals describe recent progress with SONATA-HCM?
Completion of enrollment in SONATA-HCM around mid-2026.
What is Genetically?
Genetically Informed Drug Discovery Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases.